Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
According to TipRanks, Zhu is a 5-star analyst with an average return of 23.4% and a 56.46% success rate. Zhu covers the Healthcare sector, focusing on stocks such as IDEAYA Biosciences, Revolution Medicines, and Compass Therapeutics.
In a report released on May 14, Bank of America Securities also maintained a Buy rating on the stock with a $30.00 price target.
Based on Kura Oncology’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $18.27 million and a GAAP net loss of $73.33 million. In comparison, last year the company earned a revenue of $14.11 million and had a GAAP net loss of $57.43 million
